0 Comments
0 Shares
799 Views
0 Reviews
Directory
Discover new people, create new connections and make new friends
-
Please log in to like, share and comment!
-
0 Comments 0 Shares 260 Views 0 Reviews
-
HSBC starts Constellation Energy (CEG) and Vistra (VST) at buy and models $14 billion of buybacks at eachHSBC began coverage of Constellation Energy Corporation (CEG) at buy with a $335 target and Vistra Corp. (VST) at buy with a $190 target, forecasting earnings per share growth of 19% and 21% a year to 2030. HSBC has opened coverage of two of the largest US power generators with buy ratings. It set a $335 target on Constellation Energy Corporation (CEG) and a $190 target on Vistra Corp. (VST)....0 Comments 0 Shares 969 Views 0 Reviews
-
0 Comments 0 Shares 260 Views 0 Reviews
-
STMicroelectronics kept buying back shares as its price fellSTMicroelectronics spent EUR 17.1 million buying 346,538 shares in the week to October 9. Daily purchases rose as the share price fell. Trend & Ticker breaks down the pace. STMicroelectronics N.V. (STM) published its latest share buyback update on October 12. The release covers trading from October 5 to October 9, 2026. The chipmaker bought 346,538 ordinary shares in that window, equal to...0 Comments 0 Shares 557 Views 0 Reviews
-
0 Comments 0 Shares 90 Views 0 Reviews
-
0 Comments 0 Shares 300 Views 0 Reviews
-
ServisFirst (SFBS) earns 80 cents a share, 3 cents short of forecasts, as loans outgrow depositsServisFirst Bancshares Inc. lifted third-quarter profit 33% from a year earlier and held its margin at 3.63%, but deposits fell $461 million while loans kept growing. ServisFirst Bancshares Inc. (SFBS) ended September lending about $1.05 for every $1.00 of deposits, as calculated by Trend & Ticker from the Birmingham, Alabama bank's October 19 earnings release. Deposits fell $461 million...0 Comments 0 Shares 868 Views 0 Reviews
-
0 Comments 0 Shares 326 Views 0 Reviews
-
Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in EuropeAlvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...0 Comments 0 Shares 1K Views 0 Reviews